Maia Biotechnology, INC 8-K filings

MAIA Biotechnology announced the dosing of the first patient in Taiwan for the expansion phase of its Phase 2 trial for Ateganosine in advanced non-small cell lung cancer, with current data showing median overall survival significantly exceeding known benchmarks.

MAIA Biotechnology, Inc. has entered into a stock purchase agreement with Prevail Partners, LLC to raise approximately $587,904, with proceeds earmarked to fund critical services for its ongoing Phase 3 clinical trial for advanced/metastatic non-small cell lung cancer.

MAIA Biotechnology, Inc. announced the appointment of two prominent hepatocellular carcinoma specialists to its Scientific Advisory Board, signaling progress towards a Phase 2 clinical trial for its lead candidate ateganosine in liver cancer.

MAIA Biotechnology has entered into a Master Clinical Supply Agreement with Roche to investigate the combination of its telomere-targeting agent ateganosine with Roches checkpoint inhibitor atezolizumab for hard-to-treat cancers.

MAIA Biotechnology, Inc. has entered into agreements with accredited investors to induce the exercise of outstanding warrants at a reduced price of $1.50 per share, expecting to raise approximately $328,925 in gross proceeds.

MAIA Biotechnology announced highly positive efficacy updates from its Phase 2 THIO-101 clinical trial for non-small cell lung cancer, demonstrating a median overall survival of 17.8 months and a new partial response in heavily pre-treated patients.

MAIA Biotechnology, Inc. announced the disclosure of efficacy data from its Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer and a general business presentation, both made available to the public.

MAIA Biotechnology, a clinical-stage biopharmaceutical company, announced a private placement raising approximately $695,000 to fund its Phase II THIO-101 trial and for working capital.

MAIA Biotechnology's stockholders approved an amendment to increase the company's authorized common stock from 70 million to 150 million shares.

MAIA Biotechnology's annual meeting saw stockholders approve an increase in authorized common stock and re-elect two directors.

MAIA Biotechnology has secured $1.08 million through a private placement to advance its targeted immunotherapies for cancer, specifically funding the Phase II trial of ateganosine (THIO) for NSCLC.

MAIA Biotechnology, Inc. has released a corporate presentation, available on its website, providing a business overview.

MAIA Biotechnology outlines key clinical milestones for its cancer treatment candidates, including potential FDA filings in 2026, in its 2025 Letter to Shareholders.

MAIA Biotechnology showcases efficacy data from its Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer at the European Lung Cancer Congress 2025.

MAIA Biotechnology decreased the maximum aggregate offering price of its common stock under the At The Market Offering Agreement to $11.2 million.

MAIA Biotechnology releases a presentation detailing its business operations, filed as an exhibit to a Form 8-K.

MAIA Biotechnology announces USAN Council approval for ateganosine as the nonproprietary name for its lead molecule THIO, a telomere-targeting anticancer agent.

MAIA Biotechnology plans to initiate a Phase 3 trial (THIO-104) to evaluate THIO sequenced with a checkpoint inhibitor in third-line non-small cell lung cancer patients.

MAIA Biotechnology has secured approximately $1.43 million through a private placement to accredited investors and company directors to advance its cancer immunotherapy research.

MAIA Biotechnology has entered into definitive agreements for a private placement of common stock and warrants, expected to close around February 20, 2025, to raise $2.715 million for clinical trial funding and working capital.

MAIA Biotechnology has increased the base salaries and bonus potential for its top executives, effective February 1, 2025, to incentivize performance and achievement of corporate goals.

MAIA Biotechnology reports positive efficacy updates for its Phase 2 THIO-101 trial, showing extended median overall survival in advanced non-small cell lung cancer patients.

MAIA Biotechnology has increased the maximum offering price of its common stock under an existing agreement to $30 million.

MAIA Biotechnology has been granted FDA Rare Pediatric Disease designation for THIO, a cancer treatment, for pediatric-type diffuse high-grade gliomas, potentially unlocking a valuable priority review voucher.

MAIA Biotechnology has successfully raised approximately $950,000 through a private placement of common stock and warrants to accredited investors and company directors.

MAIA Biotechnology released promising interim data from its Phase 2 THIO-101 trial, showing encouraging survival rates in advanced non-small cell lung cancer patients.

MAIA Biotechnology announced that a late-breaking abstract detailing updates from its Phase 2 THIO-101 clinical trial has been selected for presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.

MAIA Biotechnology has successfully raised $2.44 million through a private placement to accredited investors and company directors to support the manufacturing of THIO for Phase II clinical trials and for working capital.

MAIA Biotechnology reports encouraging interim survival results from its Phase 2 trial of THIO in advanced non-small cell lung cancer, showing a potential survival benefit compared to standard-of-care.

MAIA Biotechnology reports positive treatment updates from its Phase 2 THIO-101 clinical trial, showing promising results in advanced non-small cell lung cancer patients.